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Background: Real-world data regarding anti-tumor necrosis factor alpha (anti-TNFα) biologic therapy use in
psoriatic arthritis (PsA) are limited; therefore, we described treatment patterns and costs of anti-TNFα therapy in PsA
patients in the United States.
Methods: PsA patients (N = 990) aged ≥18 years who initiated anti-TNFα therapy were selected from MarketScan
claims databases (10/1/2009 to 9/30/2010). Number of patients on first- (n = 881), second- (n = 72), or third- or
greater (n = 37) line of anti-TNFα therapy, persistence, time-to-switch or modification, pharmacy and medical costs
(measured per patient per month [PPPM]) for each line of therapy were observed during the 3-year follow-up.
Results: PsA patients receiving only one line of anti-TNFα therapy remained on first-line for ~17 months while
those who switched to second- or third- or greater persisted on first-line for ~11 to 12 months, respectively. Time
to first-line modification was longer for patients who switched to third- or greater line therapy (7 months) than
those who did not switch or switched to second-line (range, ~2 to 4 months). Time-to-switch and time to first-line
modification was progressively shorter with each line of therapy for patients who received third- or greater line.
PPPM medical costs were higher for patients who did not switch ($322) than those who switched to second-
($167) or third- or greater ($217) line. PPPM pharmacy costs were greater for patients with third- or greater line
therapy ($2539) than those who did not switch ($1985) or switched to second-line ($2045).
Conclusion: While the majority of patients received only one line of anti-TNFα therapy, a subset of patients
switched to multiple lines of therapy during the 3-year follow-up period. Persistence and therapy modifications
differed between these patients and those receiving only one line. Overall medical costs were highest for patients
who did not switch, and pharmacy costs increased as patients switched to each new line of therapy.
Keywords: Anti-TNFα biologic therapy, DMARDs, Treatment patterns, Costs, Switch, Treatment modificationBackground
Psoriatic arthritis (PsA), a type of the spondyloarthritis
[1–4], is a chronic autoimmune disorder that affects the
peripheral and axial joints, nails, entheses, and is com-
monly associated with psoriatic skin lesions [5, 6].
Although symptoms can vary, patients with PsA often* Correspondence: Jacqueline-1.palmer@novartis.com
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(http://creativecommons.org/publicdomain/zesuffer from joint pain, stiffness, swelling, dactylitis, nail
psoriasis, and fatigue [6]. In addition, patients in the
later stages of disease may experience osteolysis with
destruction of the joint cartilages and boney surfaces,
potentially resulting in severe deformities [7]. In the
United States (US), approximately 30 % of patients with
psoriasis develop PsA, with the PsA prevalence esti-
mated between 0.10 and 0.25 % of the overall population
[6, 8]. PsA is associated with a number of comorbidities,
including hypertension, cardiovascular disease, obesity,
depression, and anxiety, and is linked to a decrease in
the quality of life [6, 9–12]. Direct annual healthcare
costs related to PsA were estimated to be as high as $1.9le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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accounted for 52 to 75 % of total healthcare costs, with
both direct and indirect costs reported to increase with
disease severity [6].
The American Academy of Dermatology (AAD) and
The European League Against Rheumatism (EULAR)
treatment guidelines have suggested a stepwise approach
for treating PsA based on symptoms, disease severity,
joint involvement, and extent of inflammation [13–17].
Mild disease is typically treated with nonsteroidal anti-
inflammatory drugs (NSAIDs) or intra-articular cortico-
steroid injections [13, 17]. If inflammation is persistent,
the guidelines suggest using oral nonbiologic disease-
modifying antirheumatic drugs (DMARDs), such as
methotrexate (MTX) [13, 17]. If traditional DMARDs are
unable to control the signs and symptoms of PsA, the use
of biologics is recommended [13, 17]. Biologics approved
and currently available for treating moderate-to-severe
PsA include the anti-tumor necrosis factor α (anti-TNFα)
drugs adalimumab, etanercept, golimumab, infliximab,
certolizumab pegol; and the interleukin 12 (IL-12) and
interleukin 23 (IL-23) inhibitor ustekinumab [18–23].
These agents have been reported in numerous clinical
studies as effective in managing symptoms such as dactyli-
tis, enthesitis, and spondylitis, as well as skin and nail
disease [13, 14, 17, 24–28]. Recently updated guidelines
from the Group for Research and Assessment of Psoriasis
and Psoriatic Arthritis (GRAPPA) have recommended
specific treatments based on clinical domains of disease
activity (i.e., peripheral arthritis, axial disease, enthesitis,
dactylitis, skin, or nails) [25, 26, 29, 30].
Current treatment guidelines offer no guidance in terms
of what sequence of anti-TNFα biologic therapy should be
used. Patients often start with an anti-TNFα biologic ther-
apy (i.e., first-line therapy) and switch to another line of
therapy (i.e., second-line and third-line etc.) due to lack of
effectiveness, tolerability or safety [13, 17, 25, 26, 29, 30].
If anti-TNFα biologic therapy is lacking efficacy, current
treatment guidelines suggest the addition or modification
of nonbiologic therapy (e.g., changing dose or adding or
removing a DMARD) [13, 17, 25, 26, 29, 30].
To date, no prior US studies have stratified adminis-
trative claims data by lines of anti-TNFα biologic ther-
apy [31–35]; therefore, little is known regarding how
often a patient with PsA switches from one anti-TNFα
biologic therapy to another (e.g., first anti-TNFα biologic
[first-line] to second anti-TNFα biologic [second-line]),
and whether a connection exists between treatment
modification and switching. In addition, multiple factors
may affect medical and drug costs such as functional
disability, disease severity, treatment response, dosing
schedule, and switching or modifying therapy [6, 24, 27,
34, 36, 37]. Although several studies have reported the
annual direct costs of anti-TNFα biologic therapy (i.e.,drug and administration costs) for PsA treatment [34, 35,
38, 39], none have investigated the relationship between
healthcare costs and switching of anti-TNFα biologic ther-
apy in patients with PsA. Previous US claims database
analyses have assessed the treatment patterns and health-
care costs of patients with PsA who received anti-TNFα
biologic therapy over a 1-year period [31–35, 38–40].
These studies evaluated the frequency and duration of
anti-TNFα biologic therapy (i.e., persistence, discontinu-
ation, restarting and/or switching anti-TNFα biologic ther-
apy), and the addition of another medication to the anti-
TNFα biologic therapy [31–35]. Although these claims
studies reported treatment patterns and healthcare costs
over a 1-year follow-up period, it is unclear whether these
findings are maintained over more extended periods of
time. Since PsA is a chronic disease, with patients typically
on therapy for multiple years, the purpose of this study
was to observe the treatment patterns and healthcare
costs associated with anti-TNFα biologic therapy over a 3-
year follow-up period in patients with moderate-to-severe
PsA identified from US claims databases.Methods
Data source
This study utilized a retrospective observational claims
database in the US known as Truven Health Analytics
MarketScan® Research Databases (the Commercial
Claims and Encounters Database [Commercial] and the
Medicare Supplemental and Coordination of Benefits
Database [Medicare] from January 1, 2005 to September
30, 2013. The Commercial Claims and Encounter Data-
base contains the healthcare experience of individuals
who are active employees and early retirees, and includes
coverage under fee-for-service (FFS), point of-service
(POS), and health maintenance organizations (HMOs)
[41–43], including de-identified medical claims (in-
patient, outpatient, and emergency room [ER]) and phar-
macy claims linked to plan enrollment information. The
Medicare database consists of the healthcare information
of retirees with Medicare supplemental insurance paid by
the employee, any out-of-pocket patient expenses, and
portion of the payment [42, 43]. These databases have
patient information relatd to demographics, healthcare
utilization, comprehensive prescription drug information,
and payment costs, and inpatient and outpatient detailed
cost, use, and outcomes data [42, 43].
All study data were accessed using techniques compli-
ant with the Health Insurance Portability and Account-
ability Act of 1996, and no identifiable or protected
health information was extracted during the course of
the study, hence, the study did not require informed
consent or institutional review board approval. Data are
not to be shared due to the proprietary nature [42, 43].
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The treatment identification period was from October 1,
2009 to September 30, 2010. The study population (aged
≥18 years) was selected from commercial and Medicare
health plan members identified with ≥1 claim for an
anti-TNFα biologic therapy of interest during the treatment
identification period and with ≥1 non-rule-out Inter-
national Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) claim for PsA (ICD-9-CM code
696.0) before the index date and after January 1, 2005. The
index (initiation) date was defined as the first observed
claim for use of an anti-TNFα biologic therapy. Patients
had to be continuously enrolled with medical and phar-
macy benefits 6 months prior to the index date and
through the 3-year follow-up period. The follow-up period
was defined as the 3 years that followed the index date. Pa-
tients with an ICD-9-CM code recorded in claims during
the 6-month baseline period and the 3-year follow-up
period for rheumatoid arthritis (RA) (714.x) and ankylosing
spondylitis (AS) (720.0) were excluded. Patients were also
excluded if they used an anti-TNFα biologic therapy within
6 months prior to the index date (to include only new anti-
TNFα biologic users).
Demographic and baseline patient characteristic variables
Demographic continuous and categorical variables were
age, gender, geographic region (Northeast, North central,
South, West, Unknown), and insurance type (HMO and
POS capitation, FFS], Unknown). Clinical categorical
variables were comorbidities and first-line anti-TNFα
biologic therapy. Comorbidities of interest included
hypertension (ICD-9-CM: 362.11, 401.0–405.0, 437.2),
hyperlipidemia (ICD-9-CM: 272.0–272.4), type 2 diabetes
(ICD-9-CM: 249.0, 250.0, 357.2, 362.0, 366.41), and ische-
mic heart disease (ICD-9-CM: 410.0–414.0, 414.12, 414.2,
414.3, 414.8, and 414.9).
Outcome measures
The data set and outcome measures evaluated and meth-
odology used in this study are similar to another recently
published study that focused on treatment patterns and
healthcare costs of patients with AS in the United States
over a 3-year follow-up period [44].
The current study had four key outcomes of interest
associated with anti-TNFα biologic therapy: number of
patients per line of therapy; duration of treatment; time
to treatment modification and healthcare resource costs
associated with line of treatment (medical and pharmacy
costs). For the first outcome, the number of patients on
each “n” th-line of therapy (first-, second- or third) was
reported. Treatment duration was measured as persist-
ent use of an anti-TNFα biologic (defined as time from
initiation of the treatment line to discontinuation [e.g., a
gap in treatment of >60 days]) or as time to switch tothe next treatment line, or whichever came first. Time
to first treatment modification was defined as the time
from initiation of an anti-TNFα treatment to the first
modification of that treatment. Treatment modifications
included an increase or decrease in dose of an anti-
TNFα biologic or DMARD, or an add-on, removal, or
change of a DMARD. Healthcare resource costs were re-
ported as medical costs (hospitalizations, office visits, ER
visits) and pharmacy drug costs (anti-TNFα therapy and
DMARDs) per patient per month (PPPM). Anti-TNFα
therapies of interest were etanercept [19], adalimumab
[18], infliximab [21], and golimumab [20]. Only anti-
TNFα therapies approved during the study period were
included. Non-biologic DMARDs included azathioprine
[45], hydroxychloroquine sulfate [46], leflunomide [47],
sulfasalazine [48], cyclosporine [49], methotrexate [50],
and the phosphodiesterase 4 inhibitor, apremilast [51].
Statistical analysis
All data were analyzed descriptively. Patient-level analyses
included demographics, number of patients on one or
more lines of anti-TNFα biologic therapy, number of
patients initiating each anti-TNFα agent of interest, and
number of patients who switched treatments (any switch
or ≥ one switch). Subgroup analyses reported the mean
(standard deviation [SD]) duration (days) patients per-
sisted on each line of treatment, time to switch to the next
line of treatment, time to the first treatment modification,
and time from first treatment modification to switch.
Medical costs were hospitalizations, office, and ER visits.
Pharmacy drug costs included the cost of anti-TNFα
biologic and DMARD treatment. The value for each med-
ical and pharmacy outcome was calculated as total PPPM
cost incurred from initiation of an anti-TNFα biologic
treatment to discontinuation of treatment or end of the 3-
year follow-up period (whichever came first) divided by
the number of covered members per months from initi-
ation to treatment discontinuation or end of the follow-up
period (whichever came first).
Results
Demographics and baseline characteristics
The final study population included 990 PsA patients who
started anti-TNFα biologic therapy between October 1,
2009 and September 30, 2010 (Fig. 1). At baseline (index
date), the mean (SD) average age of the study population
was 49.0 (10.9) years and was comparable across the lines
of therapy (Table 1). A lower percentage of females received
only one line of anti-TNFα biologic therapy (43.9 %)
compared with those who received a second- (58.3 %) or
third- or greater (59.5 %) line of therapy. A higher percent-
age of patients with PsA in each line of therapy were from
the Southern region of the United States compared with
other regions, and most (81.5 %) had FFS health insurance
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therapies used were etanercept (43.9 %) and adalimumab
(44.1 %). Over the 3-year follow-up, 63.5 % of patients with
PsA had at least one comorbidity—the most frequently
reported were hypertension (45.6 %), hyperlipidemia
(37.9 %), and type 2 diabetes (22.6 %) (Table 1).
Persistent use and time to switch of anti-TNFα therapy
Over the 3-year follow-up, PsA patients receiving only
one line of anti-TNFα biologic therapy persisted on theirPatients with PsA diagnosisa with ≥ 1 c
between October 1, 2009 
PsA
(n= 123
Patients with  ≥ 1 PsA diagno
Patients continuously enrolled with medical 
the index date and through 
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Fig. 1 Patient selection flowchart. aThe index date is the date of the use o
according to the ICD-9-CM code 696.0. cThe ICD-9-CM codes for RA (ICD-9
AS, ankylosing spondylitis; ICD-9-CM, International Classification of Diseases
rheumatoid arthritis; TNFα, tumor necrosis factor-αtherapy for 17.4 months (mean [SD]; 522.3 [418.9] days)
while those who switched to a second- or third- or
greater line therapy persisted on first-line therapy for
11.6 months (348.5 [308.7] days) or 10.8 months (325.2
[239.9] days), respectively (Table 2). Time to first treat-
ment modification for first-line therapy was shortest for
patients who received two lines of anti-TNFα biologic
therapy (mean [SD]; 58.4 [102.7] days or 1.9 months),
followed by those receiving one line of therapy (119.4
[208.7] days or 4 months) and those receiving three orlaim for anti-TNFα biologic therapy 
and September 30, 2010
,063)
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f the first anti-TNFα biologic. bA diagnosis of PsA was established
-CM code: 714.x) or AS (ICD-9-CM code: 720.0) were used for diagnosis.
, Ninth Revision, Clinical Modification; PsA, psoriatic arthritis; RA,
Table 1 Summary of demographics and baseline characteristics











Age (y), mean (SD) 49.1 (11.0) 48 (10.9) 48.8 (9.5) 49.0 (10.9)
Female, n (%) 387 (43.9) 42 (58.3) 22 (59.5) 451 (45.6)
US region, n (%)
Northeast 127 (14.4) 11 (15.3) 4 (10.8) 142 (14.3)
North central 209 (23.7) 11 (15.3) 8 (21.6) 228 (23.0)
South 357 (40.5) 32 (44.4) 15 (40.5) 404 (40.8)
West 182 (20.7) 18 (25.0) 10 (27.0) 210 (21.2)
Unknown 6 (0.7) 0 0 6.0 (0.6)
Health insurance, n (%)
FFS 721 (81.8) 54 (75.0) 32 (86.5) 807 (81.5)
HMO and POS capitation 137 (15.6) 18 (25.0) 5 (13.5) 160 (16.2)
Missing/unknown 23 (2.6) 0 0 23 (2.3)
Index biologic therapies, n (%)
Etanercept 389 (44.2) 31 (43.1) 15 (40.5) 435 (43.9)
Adalimumab 391 (44.4) 32 (44.4) 14 (37.8) 437 (44.1)
Infliximab 67 (7.6) 3 (4.2) 7 (18.9) 77 (7.8)
Golimumab 34 (3.9) 6 (8.3) 1 (2.7) 41 (4.1)
Comorbidities, n (%)c
Type 2 diabetes 203 (23.0) 11 (15.3) 10 (27.0) 224 (22.6)
Hypertension 400 (45.4) 33 (45.8) 18 (48.6) 451 (45.6)
Hyperlipidemia 337 (38.3) 23 (31.9) 15 (40.5) 375 (37.9)
Ischemic heart disease 75 (8.5) 4 (5.6) 4 (10.8) 83 (8.4)
Any of the above 563 (63.9) 41 (56.9) 25 (67.6) 629 (63.5)
PsA, psoriatic arthritis; FFS, fee-for-service; HMO, health maintenance organization; POS, point-of-service; SD, standard deviation; TNFα, tumor necrosis factor-α
aBiologic therapy refers to the following anti-TNFα agents: etanercept, adalimumab, infliximab, and golimumab. bAmong this group of patients, 18 (43 %) switched to a fourth-line of biologic treatment. cIdentification














Table 2 Treatment patterns for anti-TNFα biologic therapy in patients with PsA for the 3-year follow-up






Patients with Third-line or Greater
of Anti-TNFα Biologic Therapy
(n = 37)a
Persistent use of anti-TNFα biologic therapy (days), mean (SD)b
First-line 522.3 (418.9) 348.5 (308.7) 325.2 (239.9)
Second-line N/A 447.3 (327.6) 126.8 (197.9)
Third-line or greater N/A N/A 251.6 (305.2)
Time to switch anti-TNFα biologic therapy(days), mean (SD)c
First-line N/A 349.5 (308.7) 326.2 (239.9)
Second-line N/A N/A 127.8 (197.9)
Third-line or greater N/A N/A 40.2 (49.8)
Time to first modification of anti-TNFα biologic therapy (days), mean (SD)d,e
First-line 119.4 (208.7) 58.4 (102.7) 219.8 (295.4)
Second-line N/A 189.5 (226.0) 76.1 (238.9)
Third-line or greater N/A N/A 24.3 (33.3)
Time from first modification of anti-TNFα biologic therapy to switch (days), mean (SD)f
First-line N/A 385.3 (277.1) 143.5 (199.0)
Second-line N/A N/A 38.1 (53.7)
Third-line or greater N/A N/A 42.0 (65.6)
PsA psoriatic arthritis, N/A not available, SD standard deviation, TNFα tumor necrosis factor-α
aAnti-TNFα biologic therapy refers to the following anti-TNFα agents: etanercept, adalimumab, infliximab, and golimumab
bPersistent use was defined as time from initiation of the line of treatment to discontinuation (a gap in treatment of >60 days) of the line of treatment or switch to the next line of treatment (whichever came first)
cTime to switch is defined as time from initiation of the line of anti-TNFα biologic treatment to switch to the next line of anti-TNFα biologic treatment
dTime to first modification of anti-TNFα biologic therapy was defined as time from initiation of the line of anti-TNFα biologic treatment to first modification on that line of treatment
eModification of anti-TNFα biologic therapy included: biologic dose increase or dose decrease, DMARD added, changed, removed, or DMARD dose increase/decrease; Benchmark DMARD to identify first-line DMARD
change: most recent DMARD in 60-day prior to index biologics; Benchmark DMARD to identify second-/third-line DMARD change: most recent DMARD in the previous line
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In patients who received three or more lines of therapy
during the 3-year follow-up period, time to switch and
time to first treatment modification were progressively
shorter with each new line of therapy. Time from first
modification of therapy to treatment switch was longer
for patients who switched to a second line of therapy
(mean [SD]; 385.3 days [277.1] or 12.8 months) com-
pared with those who switched to a third- or greater line
of therapy (143.5 [199.0] days or 4.8 months) (Table 2).
Treatment modification of anti-TNFα biologic therapy
Modification of first-line anti-TNFα biologic treatment oc-
curred in 21.1 % of patients across all lines of therapy overTable 3 Summary of treatment modification for anti-TNFα biologic
Patients With Only First-line
Anti-TNFα Biologic
Therapy (n = 881)a
First-line, n (%)
Anti-TNFα increase 6 (0.7)
Anti-TNFα decrease 7 (0.8)
DMARD add-on 74 (8.4)
DMARD removal 59 (6.7)
DMARD drug changeb 27 (3.1)
DMARD dose increase 2 (0.2)
DMARD dose decrease 2 (0.2)






DMARD drug changeb N/A
DMARD dose increase N/A
DMARD dose decrease N/A
Any of the above N/A






DMARD dose increase N/A
DMARD dose decrease N/A
Any of the above N/A
DMARD disease-modifying antirheumatic drug, TNFα tumor necrosis factor-α
aAnti-TNFα biologic therapy refers to the following anti-TNFα agents: etanercept, ad
bFirst-line DMARD change was the most recent DMARD in 60-day prior to index ant
change was the most recent DMARD in the previous linethe follow-up period. Patients who did not switch had
fewer first-line treatment modifications (19.8 %) compared
with patients who switched to a second- (31.9 %) or third-
or greater (32.4 %) line of therapy during the follow-up
period (Table 3). In all patients, the most common modifi-
cations to first-line anti-TNFα biologic therapy were the
addition or removal of a DMARD, and change to another
DMARD (Table 3). During their second-line of therapy,
patients who received only two lines of therapy often
added a DMARD (13.9 %), while those who received at
least three or more lines of therapy commonly discontin-
ued a DMARD (21.6 %). During their third-line or greater
of therapy, the addition of a DMARD (21.6 %) or removal
of a DMARD (10.8 %) were the most common treatmenttherapy in patients with PsA for the 3-year follow-up
Patients With Second-line
Anti-TNFα Biologic
Therapy (n = 72)a
Patients with Third-line
or Greater of Anti-TNFα
Biologic Therapy (n = 37)a
0 0
0 1 (2.7)
8 (11.1) 7 (18.9)
12 (16.7) 2 (5.4)
2 (2.8) 2 (5.4)
1 (1.4) 0
0 0




4 (5.6) 8 (21.6)
3 (4.2) 2 (5.4)
0 0
0 0









alimumab, infliximab, and golimumab
i-TNFα biologic treatment and second- and third-line or greater DMARD
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therapy. Changes in dose of anti-TNFα biologic or
DMARD therapy were uncommon (≤2.8 %) across the
all lines of therapy for both patients who did and did
not switch.
Medical and pharmacy costs
PPPM medical costs were less than PPPM pharmacy costs
across all lines of treatment over the 3-year follow-up
period (Table 4). PPPM medical costs were greater for
patients who did not switch (mean [SD]; $322 [$1854])
than for those who switched to a second- ($167 [$363]) or
third- or greater ($217 [$86]) line of anti-TNFα biologic
therapy. In patients who switched to three or more lines of
therapy, the PPPM medical costs of the first-line therapy
were higher ($282 [$595]) than the second- ($79 [$99]) or
third- or greater ($107 [$88]) line of therapy. Overall,
PPPM pharmacy costs were higher for patients with three
of more lines of anti-TNFα biologic therapy (mean [SD];
$2539 [$1115]) compared with those who did not switch
therapy ($1985 [$833]) or switched to a second-line of ther-
apy ($2045 [$650]). Switching to a second-line of anti-
TNFα biologic therapy was associated with an increase in
pharmacy costs. In the group of PsA patients who received
three or more lines of anti-TNFα biologic therapy, PPPM
pharmacy costs for the third- or greater line of therapy
were lower (mean [SD]; $2126 [$2551]) than the first-





Medical Cost PPPM, Mean (SD)d
First-line $322 ($1854)
Second-line N/A
Third-line or greater N/A
Overall $322 ($1854)
Pharmacy Cost PPPM Mean (SD)e
First-line $1985 ($833)
Second-line N/A
Third-line or greater N/A
Overall $1985 ($833)
aThe value for each of the medical and pharmacy costs was calculated as total PPP
discontinuation of treatment or end of the 3-year follow-up period (whichever cam
initiation to treatment discontinuation or end of the follow-up period (whichever ca
bCosts of capitation patients were replaced with fee-for-service proxy; all costs were
cBiologic therapy refers to the following anti-TNFα agents: etanercept, adalimumab
dMedical cost = hospitalization cost + ER cost + office visit cost. Number of months i
number of months equals to 0, then it is assigned as 1
ePharmacy cost = Biologic treatment cost + DMARD treatment cost
DMARD disease-modifying antirheumatic drug, ER emergency room, PsA psoriatic a
necrosis factor-αDiscussion
In this descriptive claims-based study, treatment patterns
differed among PsA patients who remained on their first-
line of anti-TNFα biologic therapy compared with those
who switched to additional lines of anti-TNFα biologic
therapy. PsA patients who remained on their first-line anti-
TNFα biologic therapy showed longer persistence and
fewer treatment modifications of the first-line therapy com-
pared to those who switched to a second-, third- or greater
line of therapy. Time to first-line treatment modification
was longer for patients who switched to third- or greater
lines of therapy than for those who did not switch or
switched to second-line. Time-to-switch and time to first-
line modification was progressively shorter with each line
of therapy for patients who received third- or greater line.
PPPM medical costs were greater for patients who did not
switch ($322) than for patients who switched to a second-
($167) or third- or greater line ($217) of therapy. PPPM
pharmacy costs were higher than medical costs, and were
greater for patients with three or more lines of anti-TNFα
biologic therapy ($2539) compared with those with only a
first- ($1985) or a second-line ($2045) of therapy.
Similar to other US studies, our study found that eta-
nercept and adalimumab were the most common index
anti-TNFα biologic therapies [31–35]. We also found
that these two drugs were the most frequent anti-TNFα
biologic agents used in patients who switched to other









$127 ($247) $282 ($595)
$156 ($291) $79 ($99)
N/A $107 ($88.0)
$167 ($363) $217 ($86.0)
$2082 ($836) $2515 ($1800)
$2114 ($778) $2947 ($1927)
N/A $2126 ($2551)
$2045 ($650) $2539 ($1115)
M cost incurred from initiation of an anti-TNFα biologic treatment to
e first) divided by the number of covered members per months from
me first)
adjusted by consumer price index
, infliximab, and golimumab
s defined as the rounding of number of days on treatment divided by 30. If
rthritis, PPPM per patient per month, SD standard deviation, TNFα tumor
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may be influenced by dissimilarities in response to anti-
TNFα biologic therapy, comorbidities, health insurance,
change of physician, adverse events (AEs), disease char-
acteristics, disease severity, or patient preference [6, 24,
27, 34, 36, 37]. Gender may also be another factor that
has influenced switching [34]. As we observed, a lower
percentage of females persisted on their first-line therapy
compared with those who switched to either a second-
or third- or greater line of anti-TNFα biologic treatment.
In addition, several non-US studies found that women
with PsA have shorter anti-TNFα biologic drug survival
than men [52–54]. The increase in switching and the
rate of modification with each line of therapy observed
in patients who switched to three or more lines of ther-
apy may indicate a lack of treatment response, poor tol-
erance, and/or high disease severity in these patients. In
support of this, one prior non-US study found that lack
of treatment effect and AEs were the main reasons why
patients with PsA switched their anti-TNFα biologic
treatment [52].
Our findings are comparable to that of other US stud-
ies which found that the rate of switching anti-TNFα
biologic treatment over 1 year is low in PsA patients
(range 2.8 to 25 %) [31–35]. Non-US studies have also
found that only a minority of PsA patients switch anti-
TNFα biologic therapy within 1 year [54–56]. In previ-
ous US studies, patients who did not switch either
remained on their index anti-TNFα biologic, restarted
their index therapy after a treatment gap, or discontin-
ued therapy [31–35]. We did not evaluate the rate of
restarting or discontinuation of therapy.
Similar to the US study in 2014 by Zhang et al. [31], we
found that, for the overall study population, the rate of
treatment modification was low, with the most common
modifications being the addition or removal of a DMARD.
Zhang et al. found that 7 % of PsA patients added a non-
biologic DMARD to their index anti-TNFα biologic ther-
apy [31]. Our findings expand on those of Zhang et al.,
who did not assess treatment patterns associated with
multiple lines of therapy. In our study, modification of
first-line therapy was more common in patients with mul-
tiple lines of therapy compared with those who did not
switch. We found that patients who had three or more
lines of therapy added a DMARD to their first-line anti-
TNFα biologic therapy at a higher rate (18.9 %) compared
with those who did not switch (8.4 %) or who switched to
second-line therapy (11.1 %) over the 3-year follow-up
period. We also found that about 14 % of patients that
switched to second-line TNFα biologic therapy added a
DMARD to their second-line anti-TNFα biologic therapy.
In contrast, no patients who switched to three or more
lines of therapy added a DMARD to their second-line
therapy; instead, 22 % removed a DMARD. Currently, it isunclear what factors influence the rate and type of anti-
TNFα biologic treatment modification.
Previous US studies assessed the direct healthcare
costs of anti-TNFα biologic therapy [35, 38–40]. They
also did not evaluate the influence of switching on drug
and healthcare costs [35, 38–40]. We found monthly med-
ical costs were highest for patients who did not switch and
lowest for those that switched to two lines of therapy over
the 3-year follow-up period. In patients who switched to
three or more lines of anti-TNFα biologic therapy, first-line
therapy was associated with higher medical costs than sec-
ond- or third- or greater lines of treatment, which had simi-
lar associated medical costs. Monthly pharmacy costs were
higher in patients who switched compared with those who
did not and highest in those that switched to at least three
lines of treatment. The higher pharmacy costs with switch-
ing may indicate a need for additional medication possibly
due to dose escalation, disease progression, or the presence
of comorbidities in these patients. The cost of DMARDs
compared with anti-TNFα biologic therapy was not differ-
entiated in our analysis; hence, it is not clear how these
therapies influenced overall pharmacy costs.
Although several prior US studies have evaluated the
cost of anti-TNFα biologic treatment in PsA [32, 35, 38–
40], our study is the first to assess costs associated with
switching to multiple lines of anti-TNFα biologic ther-
apy. Direct comparison between our study and prior
studies is difficult due to methodological differences in
determining costs. However, in general across the stud-
ies, the annual cost for first-line therapy with anti-TNFα
biologic treatment per patient ranged from about
$17,000 to $29,000 [32, 35, 39, 40], which is similar to
the annual pharmacy cost for first-line treatment of
about $24,000 seen in our study.
The current study is a retrospective observational ana-
lysis of administrative claims databases with descriptive
findings only. In addition, we used claims data that did
not capture the reasons for switching. Therefore, we do
not know how treatment response, physician beliefs, tol-
erability, efficacy, treatment modification, or treatment
discontinuation influenced switching. This study was
limited to PsA patients with commercial health coverage
of Medicare. Consequently, it only evaluated PsA pa-
tients during the 3-year study period and it is unclear if
the findings are translatable to those that are uninsured
or on Medicaid. In addition, the limited sample size in
the latter lines of therapy limit our ability to generalize
our findings to a larger PsA population. Our study is
also limited by that fact we only evaluated continuous
users. We also excluded patients who ceased therapy for
>60 days; therefore, we did not capture patients who
stopped anti-TNFα biologic treatment and subsequently
restarted with the same or different treatment. Finally,
diagnoses on claims may be coded incorrectly or not
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ment error with respect to ICD-9 based variables. We
also did not take into consideration the potential effect
of rebates, discounts, or other price concessions.
Conclusion
This descriptive claims-based study found PsA patient
treatment patterns and healthcare costs differed depend-
ing on the number of times a patient switched their
anti-TNFα biologic therapy. Most PsA patients remained
on their first-line of therapy over the 3-year study
period. Overall, the rate of treatment modification was
low with patients who did not switch treatment having
the lowest rate of modification. Time to switch and time
to first treatment modification was progressively shorter
for patients who received at least three lines of thera-
py—potentially an indication of reduced response. The
highest PPPM medical costs were in patients that did
not switch and the highest PPPM pharmacy costs oc-
curred in patients with three or more lines of anti-TNFα
biologic therapy. The findings of this give healthcare
providers a better understanding of the real-world treat-
ment pattern and economic impact of PsA.
Abbreviations
AAD, American Academy of Dermatology; anti-TNFα, anti-tumor necrosis
factor alpha; AS, Ankylosing spondylitis; DMARD, Disease-modifying
antirheumatic drug; ER, Emergency room; EULAR, European League
Against Rheumatism; FFS, Fee-for-service; GRAPPA, Group for Research and
Assessment of Psoriasis and Psoriatic Arthritis; HMOs, Health maintenance
organizations; ICD-9-CM, International Classification of Diseases, Ninth
Revision, Clinical Modification; MTX, Methotrexate; N/A, Not available; NSAIDs,
Non-steroidal anti-inflammatory drugs; POS, Point of service; PPPM, Per
patient per month; PsA, Psoriatic arthritis; RA, Rheumatoid arthritis; SD,
Standard deviation; US, United States
Acknowledgements
Write All, Inc. received funding for its services from Novartis Pharmaceuticals
Corporation. Michelle A. Adams, BSJ, MA of Write All Inc. and a consultant to
Write All Inc, Tara Cowling, MA, MSc of Medlior Health Outcomes Research
Ltd., provided medical writing and editorial assistance for this manuscript.
Funding
Funding was provided by Novartis Pharmaceuticals Corporation, East
Hanover, NJ, USA.
Availability of data and materials
Data were purchased and accessed from The Truven Health MarketScan®
Research Databases, proprietary US research databases, which provide
datasets detailed at the patient level to for representation of the continuum
of care. Data are not to be shared due to the proprietary nature. All study
data were accessed using techniques compliant with the Health Insurance
Portability and Accountability Act of 1996, and no identifiable or protected
health information was extracted during the course of the study, hence, the
study did not require informed consent or institutional review board
approval.
Authors’ contributions
All listed authors (JP, YL, ML, VH, ZEO, MT) have met the criteria for
authorship set for by the International Committee for Medical Journal Editors
and the BMC Musculoskeletal Disorders, and have contributed equally to the
study design, writing, and revision of manuscript drafts as well as approvedthe final draft. YL and ML collected and analyzed the data and all authors
helped interpret the final data for manuscript preparation.
Competing interests
Drs. Palmer, Li, Herrera, and Ozturk are employees of Novartis
Pharmaceuticals Corporation. Minlei Liao is a senior analyst at KMK
Consulting Inc., and works as a consultant for Novartis Pharmaceuticals
Corporation. Melody Tran is fellow from Scott & White Health Plan and the
College of Pharmacy, The University of Texas at Austin and works in Health
Economics and Outcomes Research fellow at Novartis Pharmaceuticals
Corporation. The Authors declare that they have no competing interest.
Consent for publication
Not applicable.
Ethics approval and consent to participate
All study data were accessed using techniques compliant with the Health
Insurance Portability and Accountability Act of 1996, and no identifiable or
protected health information was extracted during the course of the study,
hence, the study did not require informed consent or institutional review
board approval.
Author details
1Immunology and Dermatology, Health Economics & Outcomes Research,
Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ
07936-1080, USA. 2Outcomes Research Methods & Analytics, US Health
Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East
Hanover, NJ 07936-1080, USA. 3KMK Consulting, Inc, Morristown, NJ
07960-1080, USA. 4Scott & White Health Plan, Temple, TX/College of
Pharmacy, The University of Texas at Austin, Austin, TX 78705, USA.
5Immunology and Dermatology Medical Affairs Department, Novartis
Pharmaceuticals Corporation, East Hanover, NJ 07936-1080, USA.
Received: 24 October 2015 Accepted: 27 May 2016
References
1. Spondyloarthritis (Spondyloarthropathies). http://www.rchsd.org/
documents/2014/02/spondyloarthritis.pdf. Accessed October 20 2014.
2. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R,
Dougados M, Hermann KG, Landewe R, Maksymowych W et al. The
Assessment of SpondyloArthritis international Society (ASAS) handbook: a
guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68 Suppl 2:ii1–44.
3. Rudwaleit M, Landewe R, van der Heijde D, Listing J, Brandt J, Braun J,
Burgos-Vargas R, Collantes-Estevez E, Davis J, Dijkmans B et al. The
development of Assessment of SpondyloArthritis international Society
classification criteria for axial spondyloarthritis (part I): classification of paper
patients by expert opinion including uncertainty appraisal. Ann Rheum Dis.
2009;68(6):770–6.
4. Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT,
Dougados M, Huang F, Gu J, Kirazli Y et al. The Assessment of
SpondyloArthritis International Society classification criteria for peripheral
spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;
70(1):25–31.
5. Cantini F, Niccoli L, Nannini C, Kaloudi O, Bertoni M, Cassara E. Psoriatic
arthritis: a systematic review. Int J Rheum Dis. 2010;13(4):300–17.
6. Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature
review from a global health systems perspective. P & T. 2010;35(12):680–9.
7. Krueger GG. Clinical features of psoriatic arthritis. Am J Manag Care. 2002;8(6
Suppl):S160–170.
8. About Psoriatic Arthritis. https://www.psoriasis.org/about-psoriatic-arthritis.
Accessed 30 Jun 2015.
9. Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. Dermatol
Ther. 2010;23(2):114–8.
10. Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ,
Gladman DD. Cardiovascular and other comorbidities in patients with
psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care
Res. 2011;63(12):1729–35.
11. Rosen CF, Mussani F, Chandran V, Eder L, Thavaneswaran A, Gladman DD.
Patients with psoriatic arthritis have worse quality of life than those with
psoriasis alone. Rheumatology. 2012;51(3):571–6.
Palmer et al. BMC Musculoskeletal Disorders  (2016) 17:261 Page 11 of 1112. Ackermann C, Kavanaugh A. Economic burden of psoriatic arthritis.
Pharmacoeconomics. 2008;26(2):121–9.
13. American Academy of Dermatology Work G, Menter A, Korman NJ, Elmets
CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M et
al. Guidelines of care for the management of psoriasis and psoriatic arthritis:
section 6. Guidelines of care for the treatment of psoriasis and psoriatic
arthritis: case-based presentations and evidence-based conclusions. J Am
Acad Dermatol. 2011;65(1):137–74.
14. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der
Heijde D, FitzGerald O, Aletaha D, Balint P, Boumpas D et al.
European League Against Rheumatism recommendations for the
management of psoriatic arthritis with pharmacological therapies.
Ann Rheum Dis. 2012;71(1):4–12.
15. Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P, Kavanaugh A,
Kvien TK, Landewe R, Luger T et al. Treating spondyloarthritis, including
ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an
international task force. Ann Rheum Dis. 2014;73(1):6–16.
16. Coates LC. Treating to target in psoriatic arthritis. Curr Opin Rheumatol.
2015;27(2):107–10.
17. Day MS, Nam D, Goodman S, Su EP, Figgie M. Psoriatic arthritis. J Am Acad
Orthop Surg. 2012;20(1):28–37.
18. HUMIRA (adalimumab) Prescribing Information. http://www.rxabbvie.com/
pdf/humira.pdf Accessed July 15 2015.
19. Enbrel® (etanercept) Prescribing Information. http://pi.amgen.com/united_
states/enbrel/derm/enbrel_pi.pdf. Accessed 30 Jun 2015.
20. SIMPONI (golimumab) prescribing informatiion. http://www.simponi.com/
shared/product/simponi/prescribing-information.pdf. Accessed 18 Nov 2014.
21. Remicade (infliximab) Prescribing Information. https://www.remicade.com/
shared/product/remicade/prescribing-information.pdf. Accessed 30 Jun 2015.
22. CIMZIA (certolizumab pegol) Prescribing Information. http://www.cimzia.
com/assets/pdf/Prescribing_Information.pdf. Accessed 27 Jul 2015.
23. STELARA (ustekinumab). Prescribing information. http://www.stelarainfo.
com/. Accessed 27 Jul 2015.
24. Mease P. Psoriatic arthritis and spondyloarthritis assessment and
management update. Curr Opin Rheumatol. 2013;25(3):287–96.
25. Ogdie-Beatty AR (2015) GRAPPA initiatives continue to chart the way
for psoriasis, psoriatic arthritis. PM360-Rheumatology. http://www.
pm360online.com/grappa-initiatives-continue-to-chart-the-way-for-psoriasis
-psoriatic-arthritis/. Accessed 30 Jun 2015.
26. Nash P, Lubrano E, Cauli A, Taylor WJ, Olivieri I, Gladman DD. Updated
guidelines for the management of axial disease in psoriatic arthritis. J
Rheumatol. 2014;41(11):2286–9.
27. Felquer ML, Soriano ER. New treatment paradigms in psoriatic arthritis: an
update on new therapeutics approved by the U.S. Food and Drug
Administration. Curr Opin Rheumatol. 2015;27(2):99–106.
28. Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg AS, Rodevand E,
et al. The role of methotrexate co-medication in TNF-inhibitor treatment in
patients with psoriatic arthritis: results from 440 patients included in the
NOR-DMARD study. Ann Rheum Dis. 2014;73(1):132–7.
29. Coates LC, Kavanaugh AF, Mease PJ, Ritchlin CT. GRAPPA Treatment
Recommendations: An Update from the GRAPPA 2014 Annual Meeting and
GRAPPA Meeting Adjacent to the 2014 ACR Meeting. J Rheumatol. 2015;42:
1052–5.
30. Coates LC, Ritchlin CT, Kavanaugh AF. GRAPPA treatment recommendations: an
update from the GRAPPA 2013 Annual Meeting. J Rheumatol. 2014;41(6):1237–9.
31. Zhang HF, Gauthier G, Hiscock R, Curtis JR. Treatment patterns in psoriatic
arthritis patients newly initiated on oral nonbiologic or biologic disease-
modifying antirheumatic drugs. Arthritis Res Ther. 2014;16(4):420.
32. Zhu B, Edson-Heredia E, Gatz JL, Guo J, Shuler CL. Treatment patterns and
health care costs for patients with psoriatic arthritis on biologic therapy: a
retrospective cohort study. Clin Ther. 2013;35(9):1376–85.
33. Yeaw J, Watson C, Fox KM, Schabert VF, Goodman S, Gandra SR. Treatment
patterns following discontinuation of adalimumab, etanercept, and
infliximab in a US managed care sample. Adv Ther. 2014;31(4):410–25.
34. Bonafede M, Fox KM, Watson C, Princic N, Gandra SR. Treatment patterns in
the first year after initiating tumor necrosis factor blockers in real-world
settings. Adv Ther. 2012;29(8):664–74.
35. Howe A, Eyck LT, Dufour R, Shah N, Harrison DJ. Treatment patterns and
annual drug costs of biologic therapies across indications from the Humana
commercial database. J Manag Care Spec Pharm. 2014;20(12):1236–44.36. Ogdie A, Schwartzman S, Husni ME. Recognizing and managing
comorbidities in psoriatic arthritis. Curr Opin Rheumatol. 2015;27(2):118–26.
37. Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin
K, et al. The development of candidate composite disease activity and
responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis.
2013;72(6):986–91.
38. Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.
Costs of tumor necrosis factor blockers per treated patient using real-world
drug data in a managed care population. J Manag Care Pharm. 2013;19(8):
621–30.
39. Wu N, Lee YC, Shah N, Harrison DJ. Cost of biologics per treated patient
across immune-mediated inflammatory disease indications in a pharmacy
benefit management setting: a retrospective cohort study. Clin Ther. 2014;
36(8):1231–41. 1241 e1231-1233.
40. Bonafede M, Joseph GJ, Princic N, Harrison DJ. Annual acquisition and
administration cost of biologic response modifiers per patient with
rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis. J
Med Econ. 2013;16(9):1120–8.
41. Danielson E: Health Research Data for the Real World: The MarketScan®
Databases (White Paper). 2014.
42. B.R.I.D.G.E. to data. MarketScan Commercial Claims Encounters (USA). http://
www.bridgetodata.org/node/987. Accessed 15 Jun 2015.
43. (2012) Truven Health Analytics [homepage on the Internet]. http://
truvenhealth.com/your_healthcare_focus/research/marketscan_research_
databases.aspx. Accessed 11 Oct 2014.
44. Palmer JB, LI Y, Tsang Y, Liao M, Ozturk Z: Treatment patterns and costs for
anti-TNFα therapy in patients with ankylosing spondylitis. Rheumatology
(Sunnyvale) 2015, (in press).
45. Imuran (azathioprine) Prescribing Information. http://www.accessdata.fda.gov/
drugsatfda_docs/label/2011/016324s034s035lbl.pdf. Accessed 15 Jun 2015.
46. PLAQUENIL (hydroxychloroquine sulfate) Prescribing Information. http://
www.accessdata.fda.gov/drugsatfda_docs/label/2007/009768s041lbl.pdf.
Accessed 30 Jun 2015.
47. ARAVA® (leflunomide) Prescribing Information. http://products.sanofi.com.
au/aus_pi_arava.pdf. Accessed 30 Jun 2015.
48. Azulfidine® (sulfasalazine) Prescribing Information. http://labeling.pfizer.com/
ShowLabeling.aspx?id=524. Accessed 30 Jun 2015.
49. Sandimmune® (cyclosporine) Prescribing Information. https://www.pharma.
us.novartis.com/product/pi/pdf/sandimmune.pdf. Accessed 30 Jun 2015.
50. Methotrexate (Product Monograph). http://www.pfizer.ca/sites/g/files/
g10017036/f/201410/Methotrexate_0.pdf. Accessed 30 Jun 2015.
51. OTEZLA® (apremilast) Prescribing Information. http://www.otezlapro.com/
wp-content/uploads/2015/02/otezla-prescribing-information.pdf. Accessed
30 Jun 2015.
52. Glintborg B, Ostergaard M, Krogh NS, Andersen MD, Tarp U, Loft AG,
Lindegaard HM, Holland-Fischer M, Nordin H, Jensen DV et al. Clinical
response, drug survival, and predictors thereof among 548 patients with
psoriatic arthritis who switched tumor necrosis factor alpha inhibitor
therapy: results from the Danish Nationwide DANBIO Registry. Arthritis
Rheum. 2013;65(5):1213–23.
53. Glintborg B, Ostergaard M, Dreyer L, Krogh NS, Tarp U, Hansen MS,
Rifbjerg-Madsen S, Lorenzen T, Hetland ML. Treatment response, drug
survival, and predictors thereof in 764 patients with psoriatic arthritis
treated with anti-tumor necrosis factor alpha therapy: results from the
nationwide Danish DANBIO registry. Arthritis Rheum. 2011;63(2):382–90.
54. Heiberg MS, Koldingsnes W, Mikkelsen K, Rodevand E, Kaufmann C,
Mowinckel P, Kvien TK. The comparative one-year performance of
anti-tumor necrosis factor alpha drugs in patients with rheumatoid
arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a
longitudinal, observational, multicenter study. Arthritis Rheum. 2008;
59(2):234–40.
55. Glintborg B, Ostergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, Hansen A,
Schlemmer A, Fana V, Lindegaard HM et al. Clinical response, drug survival
and predictors thereof in 432 ankylosing spondylitis patients after switching
tumour necrosis factor alpha inhibitor therapy: results from the Danish
nationwide DANBIO registry. Ann Rheum Dis. 2013;72(7):1149–55.
56. Fabbroni M, Cantarini L, Caso F, Costa L, Pagano VA, Frediani B, Manganelli
S, Galeazzi M. Drug retention rates and treatment discontinuation among
anti-TNF-alpha agents in psoriatic arthritis and ankylosing spondylitis in
clinical practice. Mediators Inflamm. 2014;2014:862969.
